IC
KPTI icon

Ikarian Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Ikarian Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.09M Buy
733,435
+188,881
+35% +$1.44M 0.33% 68
2025
Q4 		$4.01M Buy
544,554
+517,297
+1,898% +$3.16M 0.31% 72
2025
Q3 		$178K Hold
27,257
– – 0.02% 154
2025
Q2 		$117K Hold
27,257
– – 0.02% 121
2025
Q1 		$102K Sell
27,257
-3
-0% -$26 0.01% 151
2024
Q4 		$277K Sell
27,260
-30
-0.1% -$363 0.04% 144
2024
Q3 		$340K Hold
27,290
– – 0.05% 124
2024
Q2 		$355K Hold
27,290
– – 0.06% 101
2024
Q1 		$618K Buy
27,290
+623
+2% +$10.9K 0.07% 115
2023
Q4 		$346K Hold
26,667
– – 0.03% 121
2023
Q3 		$536K Hold
26,667
– – 0.06% 112
2023
Q2 		$716K Buy
26,667
+6,667
+33% +$287K 0.11% 92
2023
Q1 		$1.17M Buy
+20,000
New +$987K 0.26% 69
2022
Q2 		– Sell
-55
Closed -$6K – 173
2022
Q1 		$6K Buy
55
+3
+6% +$374 ﹤0.01% 193
2021
Q4 		$5K Buy
+52
New +$5.18K ﹤0.01% 184
2021
Q2 		– Sell
-53
Closed -$9K – 250
2021
Q1 		$9K Hold
53
– – ﹤0.01% 289
2020
Q4 		$12K Buy
+53
New +$12.3K ﹤0.01% 226
2020
Q2 		– Sell
-2,428
Closed -$700K – 192
2020
Q1 		$700K Buy
+2,428
New +$670K 0.05% 126

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Ikarian Capital's KPTI Position: Q1 2026 in Review

Ikarian Capital increased its Karyopharm Therapeutics (KPTI) stake by 35% in Q1 2026, buying an estimated $1.44M and bringing the position to 733,435 shares worth $4.09M. The position accounts for 0.33% of the portfolio, ranked #68.

Ikarian Capital first reported a position in KPTI in Q1 2020 and has held it in 18 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Ikarian Capital held 733,435 shares of Karyopharm Therapeutics worth $4.09M as of Q1 2026.
  • Ikarian Capital bought 188,881 Karyopharm Therapeutics shares in Q1 2026, an estimated $1.44M.
  • Karyopharm Therapeutics made up 0.33% of Ikarian Capital's portfolio in Q1 2026, its #68 holding.
  • Ikarian Capital first reported a position in Karyopharm Therapeutics in Q1 2020 and has held it in 18 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.